Assembly Biosciences(ASMB)
Focus: Assembly Biosciences is a public biotech company focused on small-molecule antivirals for infectious diseases, with a concentrated pipeline in chronic hepatitis B and herpes simplex virus programs. At 51-200 employees, it operates as a lean, research-intensive organization.
Profile data last refreshed 17h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Employees
51-200
Open Jobs
2-2 this month
Stable — net -2 jobs in 30d
0 added, 2 removed. Backfill posture.
Should You Work at Assembly Biosciences?
AI assessmentSuitable for early-career scientists seeking deep antiviral expertise in a pre-profitability biotech, but high execution and funding risk requires comfort with biotech volatility.
Why Work Here
- Focused pipeline with 4 Phase 2 programs in high-value hepatitis B indication; vebicorvir and ABI-H2158 represent near-term catalysts
- Perfect 16/16 H1B approval rate in 2023 signals strong visa sponsorship and international hiring flexibility
Data completeness
5/9 — Partial
Company HealthSolid
Pipeline
Early-stage
17 total
LOE Risk
Protected
No near-term cliffs
Hiring
Slowing
Jobs decreasing
Pipeline & Clinical Trials
Quality Improvement
Type 2 Diabetes MellitusVideo-based Task-specific Training
StrokeClinical Trials (1)
Help build intelligence for Assembly Biosciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.